• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mol Med Rep . Predictive prognostic biomarkers in patients with COVID‑19 infection

tetano

Editor, Senior Moderator
Mol Med Rep


. 2023 Jan;27(1):15.
doi: 10.3892/mmr.2022.12902. Epub 2022 Dec 1.
Predictive prognostic biomarkers in patients with COVID‑19 infection


Shunsuke Fukui[SUP] 1 [/SUP], Kohei Ikeda[SUP] 1 [/SUP], Mayu Kobayashi[SUP] 1 [/SUP], Keigo Nishida[SUP] 1 [/SUP], Keita Yamada[SUP] 1 [/SUP], Shotaro Horie[SUP] 1 [/SUP], Yasuaki Shimada[SUP] 1 [/SUP], Hiroto Miki[SUP] 1 [/SUP], Hiroki Goto[SUP] 1 [/SUP], Koken Hayashi[SUP] 1 [/SUP], Yuuichi Nakazawa[SUP] 1 [/SUP], Hiroki Mizutani[SUP] 1 [/SUP], Toshitaka Kamon[SUP] 1 [/SUP], Yusuke Tanigaito[SUP] 1 [/SUP], Shuji Kodama[SUP] 1 [/SUP], Takashi Kato[SUP] 1 [/SUP], Yuuki Nishiura[SUP] 1 [/SUP], Daisuke Suga[SUP] 1 [/SUP], Toshikazu Terashima[SUP] 1 [/SUP], Yuhuko Ichikawa[SUP] 2 [/SUP], Isao Moritani[SUP] 1 [/SUP], Akitaka Yamamoto[SUP] 3 [/SUP], Kei Takaba[SUP] 4 [/SUP], Kouji Yasumoto[SUP] 4 [/SUP], Hideo Wada[SUP] 1 [/SUP], Katsuya Shiraki[SUP] 1 [/SUP]



Affiliations

Abstract

The present study aimed to identify useful biomarkers to predict deterioration in patients with coronavirus disease 2019 (COVID‑19). A total of 201 COVID‑19 patients were classified according to their disease severity into non‑severe (n=125) and severe (n=76) groups, and the behavior of laboratory biomarkers was examined according to the prognosis. Neutrophil count, aspartate aminotransferase (AST), alanine aminotransferase, lactate dehydrogenase (LDH), C‑reactive protein (CRP), sialylated carbohydrate antigen KL‑6 (KL‑6), procalcitonin (PCT), presepsin (PSP) and D‑dimer levels were significantly higher, and lymphocyte count and platelet count were significantly lower in the non‑severe group compared with the severe group. In the non‑severe group, ROC analysis demonstrated that only four biomarkers, CRP, PSP, AST and LDH were useful for differentiating the prognosis between improvement and deterioration subgroups. No strong correlation was revealed for any of the markers. Multivariate analysis identified CRP as a significant prognostic factor in non‑severe cases (odds ratio, 41.45; 95% confidence interval, 4.91‑349.24; P<0.001). However, there were no blood biomarkers that could predict the outcome of patients in the severe group. Overall, several blood markers changed significantly according to disease severity in the course of COVID‑19 infection. Among them, CRP, PSP, LDH and AST were the most reliable markers for predicting the patient's prognosis in non‑severe COVID‑19 cases.

Keywords: biomarker; coronavirus disease 2019; prognosis; risk factor.
 
Back
Top Bottom